Brief: BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

Biomx

31/03/2025 11:58

March 31 (Reuters) - Biomx Inc PHGE.A:

BIOMX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TRIAL EVALUATING BX211 FOR THE TREATMENT OF DIABETIC FOOT OSTEOMYELITIS (DFO)

BIOMX INC - BX211 FOUND TO BE SAFE AND WELL-TOLERATED

BIOMX INC -PLANNING FOR A PHASE 2/3 TRIAL OF BX211, PENDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) FEEDBACK

Source text: ID:nGNX1VmHGn

Further company coverage: PHGE.A

 ((Reuters.Briefs@thomsonreuters.com;))